AXS-05 shown to effectively manage depression symptoms
The drug was shown to regulate mood by improving the communication between brain cells and increasing levels of serotonin, noradrenaline and dopamine.
Blockbuster-to-be for depression flunks pivotal Phase III
Sage Therapeutics was aiming to enter a bigger market, through the potential launch of SAGE-217.
Rare neurological disease gene therapy gains from accelerated review
Metachromatic leukodystrophy could be the next indication to witness the impact of gene therapy.
Blood-brain barrier penetrating drug technology could be key to treating Alzheimer’s disease
The blood-brain barrier (BBB) is a protective element that restricts the movement of molecules between the bloodstream and central nervous system.
NOURIANZ (istradefylline) for the Treatment of Parkinson’s Disease
NOURIANZ (istradefylline) is indicated as adjunctive therapy to levodopa and carbidopa medications in adult patients with Parkinson’s disease (PD) to treat “off” episodes, caused when existing medications are ineffective and lead to an increase in PD symptoms.
Majority of Alzheimer’s disease clinical trials in the US parked in Phase I
Alzheimer’s disease is the most common type of dementia and the sixth leading cause of death in the US.
Acadia initiates Phase III study of trofinetide to treat Rett syndrome
Acadia Pharmaceuticals has initiated the Phase III LAVENDER placebo-controlled study of trofinetide to treat girls and young women with Rett syndrome.
UCB to conduct bridging study of UCB0107 in progressive supranuclear palsy this year
The bridging study will be necessary to provide the safety and pharmacokinetic data needed to advance the anti-tau drug into a Phase III trial planned for 2020.
Theravance to recruit 120 trial sites for Phase III trial in neurogenic orthostatic hypotension
neurogenic orthostatic hypotension is a rare subtype of orthostatic hypotension caused by underlying neurologic disorders that affect a specific part of the autonomic nervous system.